Equities research analysts predict that FibroGen Inc (NASDAQ:FGEN) will report sales of $30.68 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for FibroGen’s earnings. The lowest sales estimate is $23.00 million and the highest is $41.30 million. FibroGen posted sales of $29.03 million during the same quarter last year, which suggests a positive year over year growth rate of 5.7%. The business is scheduled to announce its next earnings results on Thursday, November 14th.

On average, analysts expect that FibroGen will report full-year sales of $285.23 million for the current year, with estimates ranging from $264.80 million to $320.30 million. For the next year, analysts expect that the company will report sales of $344.59 million, with estimates ranging from $221.70 million to $505.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for FibroGen.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $1.75. The firm had revenue of $191.57 million during the quarter, compared to analysts’ expectations of $29.03 million. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The firm’s quarterly revenue was up 335.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) EPS.

A number of equities research analysts recently weighed in on the company. Mizuho restated a “buy” rating and set a $65.00 price objective on shares of FibroGen in a research note on Sunday, August 11th. ValuEngine cut FibroGen from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. William Blair restated a “hold” rating on shares of FibroGen in a research note on Tuesday, July 2nd. BidaskClub cut FibroGen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research note on Tuesday, August 13th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $61.00.

Shares of NASDAQ FGEN traded down $1.81 during mid-day trading on Friday, reaching $41.72. 520,837 shares of the company were exchanged, compared to its average volume of 567,945. The company has a quick ratio of 9.71, a current ratio of 9.73 and a debt-to-equity ratio of 0.07. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of -40.50 and a beta of 1.86. FibroGen has a 1 year low of $33.51 and a 1 year high of $61.95. The firm has a 50-day moving average of $45.76 and a 200 day moving average of $47.66.

In other FibroGen news, CEO Thomas B. Neff sold 18,400 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $45.65, for a total value of $839,960.00. Following the completion of the sale, the chief executive officer now directly owns 2,379,710 shares in the company, valued at $108,633,761.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $38.21, for a total value of $1,514,491.56. Following the completion of the sale, the chief executive officer now owns 2,480,780 shares of the company’s stock, valued at $94,790,603.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 266,574 shares of company stock valued at $11,661,395. 8.96% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC grew its holdings in FibroGen by 150.0% during the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 300 shares during the period. FTB Advisors Inc. acquired a new stake in FibroGen during the first quarter worth about $27,000. Manchester Capital Management LLC acquired a new stake in FibroGen during the first quarter worth about $39,000. Cornerstone Advisors Inc. grew its holdings in FibroGen by 672.8% during the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 693 shares during the period. Finally, Quadrant Capital Group LLC acquired a new stake in FibroGen during the first quarter worth about $45,000. Institutional investors own 64.60% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: 52-Week High/Low

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.